Evidence map›Paper›PMID 38609164›Full record

ArticleThe British journal of ophthalmology2024

Relapse in ocular tuberculosis: relapse rate, risk factors and clinical management in a non-endemic country.

Ikhwanuliman Putera, Josianne C E M Ten Berge, Alberta A H J Thiadens, Willem A Dik, Rupesh Agrawal, P Martin van Hagen, Rina La Distia Nora, Saskia M Rombach

Registry-linked trialAbstract read
In one paragraph

Article in The British journal of ophthalmology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05005637 (Antitubercular Treatment for Uveitis of Undetermined Cause with Positive QuantiFERON-TB Gold Plus), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05005637 phase2completednot on this map

Antitubercular Treatment for Uveitis of Undetermined Cause with Positive QuantiFERON-TB Gold Plus: a Randomized Clinical Trial

TypeinterventionalSponsorFakultas Kedokteran Universitas IndonesiaRan2021 to 2024Enrolled78ConditionsTuberculous UveitisArmsAnti Tuberculosis Drug, Methylprednisolone
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ikhwanuliman PuteraDepartment of Ophthalmology, Faculty of Medicine, University of Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia i.putera@erasmusmc.nl s.rombach@erasmusmc.nl.ORCID 0000-0002-9350-5133
Josianne C E M Ten BergeDepartment of Ophthalmology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Alberta A H J ThiadensDepartment of Ophthalmology, Erasmus University Medical Centre, Rotterdam, The Netherlands.ORCID 0000-0002-4911-9462
Willem A DikLaboratory Medical Immunology, Department of Immunology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Rupesh AgrawalNational Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore.
P Martin van HagenLaboratory Medical Immunology, Department of Immunology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Rina La Distia NoraDepartment of Ophthalmology, Faculty of Medicine, University of Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.ORCID 0000-0002-7026-5341
Saskia M RombachDepartment of Internal Medicine Section Allergy and Clinical Immunology, Erasmus University Medical Centre, Rotterdam, The Netherlands i.putera@erasmusmc.nl s.rombach@erasmusmc.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo assess the risk of uveitis relapse in ocular tuberculosis (OTB) following clinical inactivity, to analyse clinical factors associated with relapses and to describe the management strategies for relapses.

methodsA retrospective study was conducted on a 10-year patient registry of patients with OTB diagnosed at Erasmus MC in Rotterdam, The Netherlands. Time-to-relapse of uveitis was evaluated with Kaplan-Meier curve and risk factors for relapses were analysed.

results93 OTB cases were identified, of which 75 patients achieved clinical inactivity following treatment. The median time to achieve uveitis inactivity was 3.97 months. During a median follow-up of 20.7 months (Q1-Q3: 5.2-81.2) after clinical inactivity, uveitis relapse occurred in 25 of these 75 patients (33.3%). Patients who were considered poor treatment responders for their initial uveitis episode had a significantly higher risk of relapse after achieving clinical inactivity than good responders (adjusted HR=3.84, 95% CI: 1.28 to 11.51). 13 of the 25 relapsed patients experienced multiple uveitis relapse episodes, accounting for 78 eye-relapse episodes during the entire observation period. Over half (46 out of 78, 59.0%) of these episodes were anterior uveitis. A significant number of uveitis relapse episodes (31 episodes, 39.7%) were effectively managed with topical corticosteroids.

conclusionsOur results suggest that approximately one-third of patients with OTB will experience relapse after achieving clinical inactivity. The initial disease course and poor response to treatment predict the likelihood of relapse in the long-term follow-up. Topical corticosteroids were particularly effective in relapse presenting as anterior uveitis.

Indexed as

Antitubercular AgentsRecurrenceTuberculosis, OcularAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedNetherlandsRegistriesRetrospective StudiesRisk FactorsUveitisYoung AdultAntitubercular AgentsInfectionInflammationPrognosisRisk FactorsTreatment Medical

Identifiers

PMID38609164
PMCPMC11671955

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.